Telomerase activity promotes osteoblast differentiation by modulating IGF-signaling pathway

Biogerontology

Volumn 16, Issue 6, 2015, Pages 733-745

  Saeed, Hamid ^a,b   Qiu, Weimin ^a   Li, Chen ^a   Flyvbjerg, Allan ^c   Abdallah, Basem M ^a,d   Kassem, Moustapha ^a,e  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b UNIVERSITY OF THE PUNJAB   (Pakistan)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d HELWAN UNIVERSITY   (Egypt)

^e KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Aging; Bone; Bone marrow stromal stem cells; IGF; Osteoblasts; Telomerase

Indexed keywords

ALKALINE PHOSPHATASE; PICROPODOPHYLLIN; PROTEIN INHIBITOR; PROTEIN KINASE B; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C RECEPTOR; TELOMERASE; UNCLASSIFIED DRUG; PHOSPHATIDYLINOSITOL 3 KINASE; RNA; SOMATOMEDIN BINDING PROTEIN; TELOMERASE RNA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; BONE MARROW STROMA CELL; CELL DIFFERENTIATION; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENE LOSS; GENETIC GAIN; HUMAN; HUMAN CELL; IGF1 GENE; IGF2 GENE; IGF2R GENE; IGFBP5 GENE; IGFBP6 GENE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BLOOD; CELL AGING; CELL CULTURE; CYTOLOGY; DEFICIENCY; ENZYME ACTIVATION; GENETICS; KNOCKOUT MOUSE; MESENCHYMAL STROMA CELL; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; CELL AGING; CELL DIFFERENTIATION; CELLS, CULTURED; ENZYME ACTIVATION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MESENCHYMAL STROMAL CELLS; MICE; MICE, KNOCKOUT; OSTEOBLASTS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA; SIGNAL TRANSDUCTION; SOMATOMEDINS; TELOMERASE;

EID: 84943816720     PISSN: 13895729     EISSN: 15736768     Source Type: Journal    
DOI: 10.1007/s10522-015-9596-6     Document Type: Article

References (77)

1. Abdallah BM, Haack-Sorensen M, Burns JS, Elsnab B, Jakob F, Hokland P, Kassem M (2005) Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite [corrected] extensive proliferation. Biochem Biophys Res Commun 326:527–538
2. Abdallah BM, Ding M, Jensen CH, Ditzel N, Flyvbjerg A, Jensen TG, Dagnaes-Hansen F, Gasser JA, Kassem M (2007) Dlk1/FA1 is a novel endocrine regulator of bone and fat mass and its serum level is modulated by growth hormone. Endocrinology 148:3111–3121
3. Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC (2002) Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 62:3876–3882
4. Almeida M, Han L, Martin-Millan M, O’Brien CA, Manolagas SC (2007) Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem 282:27298–27305
5. Baege AC, Disbrow GL, Schlegel R (2004) IGFBP-3, a marker of cellular senescence, is overexpressed in human papillomavirus-immortalized cervical cells and enhances IGF-1-induced mitogenesis. J Virol 78:5720–5727
6. Barrett-Connor E, Goodman-Gruen D (1998) Gender differences in insulin-like growth factor and bone mineral density association in old age: the Rancho Bernardo study. J Bone Miner Res 13:1343–1349
7. Baxter RC, Martin JL (1989) Binding proteins for the insulin-like growth factors: structure, regulation and function. Prog Growth Factor Res 1:49–68
8. Bellon M, Nicot C (2008) Central role of PI3K in transcriptional activation of hTERT in HTLV-I-infected cells. Blood 112:2946–2955
9. Boonen S, Mohan S, Dequeker J, Aerssens J, Vanderschueren D, Verbeke G, Broos P, Bouillon R, Baylink DJ (1999) Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis. J Bone Miner Res 14:2150–2158
10. Breitschopf K, Zeiher AM, Dimmeler S (2001) Pro-atherogenic factors induce telomerase inactivation in endothelial cells through an Akt-dependent mechanism. FEBS Lett 493:21–25
11. Brown-Borg HM, Borg KE, Meliska CJ, Bartke A (1996) Dwarf mice and the ageing process. Nature 384:33
12. Chapman MD, Keir G, Petzold A, Thompson EJ (2006) Measurement of high affinity antibodies on antigen-immunoblots. J Immunol Methods 310:62–66
13. Conover CA (2008) Insulin-like growth factor-binding proteins and bone metabolism. Am J Physiol Endocrinol Metab 294:E10–E14
14. de Bernardes JB, Schneeberger K, Vera E, Tejera A, Harley CB, Blasco MA (2011) The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging Cell 10:604–621
15. de Bernardes JB, Vera E, Schneeberger K, Tejera AM, Ayuso E, Bosch F, Blasco MA (2012) Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO Mol Med 4:691–704
16. Ernst M, Heath JK, Rodan GA (1989) Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones. Endocrinology 125:825–833
17. Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824–854
18. Flyvbjerg A, Kessler U, Dorka B, Funk B, Orskov H, Kiess W (1992) Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats. Diabetologia 35:589–593
19. Fresno Vara JA, Casado E, De CJ, Cejas P, Belda-Iniesta C, Gonzalez-Baron M (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30:193–204
20. Fujita T, Azuma Y, Fukuyama R, Hattori Y, Yoshida C, Koida M, Ogita K, Komori T (2004) Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol 166:85–95
21. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526–1536
22. Ghosh-Choudhury N, Abboud SL, Nishimura R, Celeste A, Mahimainathan L, Choudhury GG (2002) Requirement of BMP-2-induced phosphatidylinositol 3-kinase and Akt serine/threonine kinase in osteoblast differentiation and Smad-dependent BMP-2 gene transcription. J Biol Chem 277:33361–33368
23. Giustina A, Mazziotti G, Canalis E (2008) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29:535–559
24. Gomez-Garcia L, Sanchez FM, Vallejo-Cremades MT, de Segura IA, del Campo EM (2005) Direct activation of telomerase by GH via phosphatidylinositol 3′-kinase. J Endocrinol 185:421–428
25. Grey A, Chen Q, Xu X, Callon K, Cornish J (2003) Parallel phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells. Endocrinology 144:4886–4893
26. Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A (1996) Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab 81:3864–3870
27. Haendeler J, Hoffmann J, Rahman S, Zeiher AM, Dimmeler S (2003) Regulation of telomerase activity and anti-apoptotic function by protein-protein interaction and phosphorylation. FEBS Lett 536:180–186
28. Heeg S, Hirt N, Queisser A, Schmieg H, Thaler M, Kunert H, Quante M, Goessel G, von Werder A, Harder J, Beijersbergen R, Blum HE, Nakagawa H, Opitz OG (2011) EGFR overexpression induces activation of telomerase via PI3 K/AKT-mediated phosphorylation and transcriptional regulation through Hif1-alpha in a cellular model of oral-esophageal carcinogenesis. Cancer Sci 102:351–360
29. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31:e15
30. Jiang J, Lichtler AC, Gronowicz GA, Adams DJ, Clark SH, Rosen CJ, Kream BE (2006) Transgenic mice with osteoblast-targeted insulin-like growth factor-I show increased bone remodeling. Bone 39:494–504
31. Kang SS, Kwon T, Kwon DY, Do SI (1999) Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 274:13085–13090
32. Kassem M, Marie PJ (2011) Senescence-associated intrinsic mechanisms of osteoblast dysfunctions. Aging Cell 10:191–197
33. Kassem M, Mosekilde L, Eriksen EF (1993) 1,25-dihydroxyvitamin D3 potentiates fluoride-stimulated collagen type I production in cultures of human bone marrow stromal osteoblast-like cells. J Bone Miner Res 8:1453–1458
34. Kassem M, Okazaki R, De LD, Harris SA, Robinson JA, Spelsberg TC, Conover CA, Riggs BL (1996) Potential mechanism of estrogen-mediated decrease in bone formation: estrogen increases production of inhibitory insulin-like growth factor-binding protein-4. Proc Assoc Am Physicians 108:155–164
35. Kawamura N, Kawaguchi H (2007) Regulation of bone mass by PI3 kinase/Akt signaling. Nihon Rinsho 65(Suppl 9):67–70
36. Kawamura N, Kugimiya F, Oshima Y, Ohba S, Ikeda T, Saito T, Shinoda Y, Kawasaki Y, Ogata N, Hoshi K, Akiyama T, Chen WS, Hay N, Tobe K, Kadowaki T, Azuma Y, Tanaka S, Nakamura K, Chung UI, Kawaguchi H (2007) Akt1 in osteoblasts and osteoclasts controls bone remodeling. PLoS ONE 2:e1058
37. Kawauchi K, Ihjima K, Yamada O (2005) IL-2 increases human telomerase reverse transcriptase activity transcriptionally and posttranslationally through phosphatidylinositol 3′-kinase/Akt, heat shock protein 90, and mammalian target of rapamycin in transformed NK cells. J Immunol 174:5261–5269
38. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, Ng L, Simpson DM, Rosenfeld RG (1996) Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 28:619–637
39. Khosla S, Riggs BL (2005) Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin North Am 34:1015–1030 xi
40. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, Shimomura I, Takayama Y, Herz J, Kahn CR, Rosenblatt KP, Kuro-o M (2005) Suppression of aging in mice by the hormone Klotho. Science 309:1829–1833
41. Kveiborg M, Flyvbjerg A, Rattan SI, Kassem M (2000) Changes in the insulin-like growth factor-system may contribute to in vitro age-related impaired osteoblast functions. Exp Gerontol 35:1061–1074
42. Langdahl BL, Kassem M, Moller MK, Eriksen EF (1998) The effects of IGF-I and IGF-II on proliferation and differentiation of human osteoblasts and interactions with growth hormone. Eur J Clin Invest 28:176–183
43. Langlois JA, Rosen CJ, Visser M, Hannan MT, Harris T, Wilson PW, Kiel DP (1998) Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart study. J Clin Endocrinol Metab 83:4257–4262
44. Laviola L, Natalicchio A, Perrini S, Giorgino F (2008) Abnormalities of IGF-I signaling in the pathogenesis of diseases of the bone, brain, and fetoplacental unit in humans. Am J Physiol Endocrinol Metab 295:E991–E999
45. Levine AJ, Feng Z, Mak TW, You H, Jin S (2006) Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 20:267–275
46. Liu X, Bruxvoort KJ, Zylstra CR, Liu J, Cichowski R, Faugere MC, Bouxsein ML, Wan C, Williams BO, Clemens TL (2007) Lifelong accumulation of bone in mice lacking Pten in osteoblasts. Proc Natl Acad Sci USA 104:2259–2264
47. Liu JM, Zhao HY, Ning G, Chen Y, Zhang LZ, Sun LH, Zhao YJ, Xu MY, Chen JL (2008) IGF-1 as an early marker for low bone mass or osteoporosis in premenopausal and postmenopausal women. J Bone Miner Metab 26:159–164
48. Manolagas SC (2010) From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 31:266–300
49. Muck C, Micutkova L, Zwerschke W, Jansen-Durr P (2008) Role of insulin-like growth factor binding protein-3 in human umbilical vein endothelial cell senescence. Rejuvenation Res 11:449–453
50. Mukherjee A, Rotwein P (2009) Akt promotes BMP2-mediated osteoblast differentiation and bone development. J Cell Sci 122:716–726
51. Nicolas V, Prewett A, Bettica P, Mohan S, Finkelman RD, Baylink DJ, Farley JR (1994) Age-related decreases in insulin-like growth factor-I and transforming growth factor-beta in femoral cortical bone from both men and women: implications for bone loss with aging. J Clin Endocrinol Metab 78:1011–1016
52. Ohlsson C, Mellstrom D, Carlzon D, Orwoll E, Ljunggren O, Karlsson MK, Vandenput L (2011) Older men with low serum IGF-1 have an increased risk of incident fractures: the MrOS Sweden study. J Bone Miner Res 26:865–872
53. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ (2004) Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 103:1662–1668
54. Perrini S, Natalicchio A, Laviola L, Cignarelli A, Melchiorre M, De SF, Caccioppoli C, Leonardini A, Martemucci S, Belsanti G, Miccoli S, Ciampolillo A, Corrado A, Cantatore FP, Giorgino R, Giorgino F (2008) Abnormalities of insulin-like growth factor-I signaling and impaired cell proliferation in osteoblasts from subjects with osteoporosis. Endocrinology 149:1302–1313
55. Perrini S, Laviola L, Carreira MC, Cignarelli A, Natalicchio A, Giorgino F (2010) The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. J Endocrinol 205:201–210
56. Post S, Abdallah BM, Bentzon JF, Kassem M (2008) Demonstration of the presence of independent pre-osteoblastic and pre-adipocytic cell populations in bone marrow-derived mesenchymal stem cells. Bone 43:32–39
57. Qiu W, Hu Y, Andersen TE, Jafari A, Li N, Chen W, Kassem M (2010) Tumor necrosis factor receptor superfamily member 19 (TNFRSF19) regulates differentiation fate of human mesenchymal (stromal) stem cells through canonical Wnt signaling and C/EBP. J Biol Chem 285:14438–14449
58. Raucci A, Bellosta P, Grassi R, Basilico C, Mansukhani A (2008) Osteoblast proliferation or differentiation is regulated by relative strengths of opposing signaling pathways. J Cell Physiol 215:442–451
59. Rosen CJ (2004) Insulin-like growth factor I and bone mineral density: experience from animal models and human observational studies. Best Pract Res Clin Endocrinol Metab 18:423–435
60. Rosen CJ, Dimai HP, Vereault D, Donahue LR, Beamer WG, Farley J, Linkhart S, Linkhart T, Mohan S, Baylink DJ (1997) Circulating and skeletal insulin-like growth factor-I (IGF-I) concentrations in two inbred strains of mice with different bone mineral densities. Bone 21:217–223
61. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J, Bilezikian JP (1998) Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 83:2286–2290
62. Saeed H, Abdallah BM, Ditzel N, Catala-Lehnen P, Qiu W, Amling M, Kassem M (2011) Telomerase-deficient mice exhibit bone loss owing to defects in osteoblasts and increased osteoclastogenesis by inflammatory microenvironment. J Bone Miner Res 26:1494–1505
63. Schmid C, Rutishauser J, Schlapfer I, Froesch ER, Zapf J (1991) Intact but not truncated insulin-like growth factor binding protein-3 (IGFBP-3) blocks IGF I-induced stimulation of osteoblasts: control of IGF signalling to bone cells by IGFBP-3-specific proteolysis? Biochem Biophys Res Commun 179:579–585
64. Seck T, Scheidt-Nave C, Leidig-Bruckner G, Ziegler R, Pfeilschifter J (2001) Low serum concentrations of insulin-like growth factor I are associated with femoral bone loss in a population-based sample of postmenopausal women. Clin Endocrinol (Oxf) 55:101–106
65. Severgnini S, Lowenthal DT, Millard WJ, Simmen FA, Pollock BH, Borst SE (1999) Altered IGF-I and IGFBPs in senescent male and female rats. J Gerontol A Biol Sci Med Sci 54:B111–B115
66. Shie JH, Liu HT, Kuo HC (2012) Increased cell apoptosis of urothelium mediated by inflammation in interstitial cystitis/painful bladder syndrome. Urology 79:484–513
67. Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SI, Jensen TG, Kassem M (2002) Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol 20:592–596
68. Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Tornell J, Isaksson OG, Jansson JO, Ohlsson C (1999) Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 96:7088–7092
69. Sugimoto T, Nishiyama K, Kuribayashi F, Chihara K (1997) Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res 12:1272–1279
70. Tsugawa K, Jones MK, Akahoshi T, Moon WS, Maehara Y, Hashizume M, Sarfeh IJ, Tarnawski AS (2003a) Abnormal PTEN expression in portal hypertensive gastric mucosa: a key to impaired PI 3-kinase/Akt activation and delayed injury healing? FASEB J 17:2316–2318
71. Tsugawa K, Jones MK, Akahoshi T, Moon WS, Maehara Y, Hashizume M, Sarfeh IJ, Tarnawski AS (2003b) Abnormal PTEN expression in portal hypertensive gastric mucosa: a key to impaired PI 3-kinase/Akt activation and delayed injury healing? FASEB J 17:2316–2318
72. Xia L, Wang XX, Hu XS, Guo XG, Shang YP, Chen HJ, Zeng CL, Zhang FR, Chen JZ (2008) Resveratrol reduces endothelial progenitor cells senescence through augmentation of telomerase activity by Akt-dependent mechanisms. Br J Pharmacol 155:387
73. Xian L, Wu X, Pang L, Lou M, Rosen CJ, Qiu T, Crane J, Frassica F, Zhang L, Rodriguez JP, Xiaofeng J, Shoshana Y, Shouhong X, Argiris E, Mei W, Xu C (2012) Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med 18:1095–1101
74. Xue P, Wu X, Zhou L, Ma H, Wang Y, Liu Y, Ma J, Li Y (2013) IGF1 promotes osteogenic differentiation of mesenchymal stem cells derived from rat bone marrow by increasing TAZ expression. Biochem Biophys Res Commun 433:226–231
75. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D (2002) Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Investig 110:771–781
76. Yamaguchi T, Kanatani M, Yamauchi M, Kaji H, Sugishita T, Baylink DJ, Mohan S, Chihara K, Sugimoto T (2006) Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3, -4, and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women. Calcif Tissue Int 78:18–24
77. Ye J, Renault VM, Jamet K, Gilson E (2014) Transcriptional outcome of telomere signalling. Nat Rev Genet 15:491–503